<DOC>
	<DOCNO>NCT00439062</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy , safety , tolerability roxithromycin patient rheumatoid arthritis .</brief_summary>
	<brief_title>Treatment Rheumatoid Arthritis With Roxithromycin</brief_title>
	<detailed_description>This 6-month , monocentre , randomize , double-blind , placebo-controlled study . We treat 100 patient rheumatoid arthritis either once-daily oral roxithromycin ( 300 mg ) daily oral placebo 6 month . The primary efficacy variable percentage patient 20 percent improvement accord American College Rheumatology ( ACR ) criterion ( ACR 20 response ) six month . Secondary outcome measure 50 percent improvement 70 percent improvement accord ACR criterion ( ACR 50 response ACR 70 response , respectively ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Roxithromycin</mesh_term>
	<criteria>RA accord 1987 American Rheumatism Association criteria19 , age 18 70 year . Patients required inadequate response one four DMARDs ( azathioprine , methotrexate , sulfasalazine , penicillamine , hydroxychloroquine , oral injectable gold ) ; inadequate response define discontinuation therapy lack effect . If patient receive DMARDs , require complete DMARD washout period last least 1 month start study drug treatment ; DMARDs permit study . Patients receive nonsteroidal antiinflammatory drug , prednisone ( 10 mg daily less ) , eligible dos stable least four week study period continue stable study period . Patients allow receive intraarticular corticosteroid . Patients active disease enrollment ( DMARD washout period ) , define 12 tender joint , 10 swollen joint , least one following : erythrocyte sedimentation rate ( ESR ) least 28 mm/hr , Creactive protein ( CRP ) level great 2.0 mg/dL , morning stiffness least 45 minute . A negative pregnancy test result require nonmenopausal female patient . In female patient childbearing potential urine pregnancy test do baseline pregnant woman exclude . Other exclusion criterion include impaired hepatic enzyme test , impair renal function , chronic/recurrent infection ( e.g. , chronic bronchitis , recurrent sinusitis ) , infection ( e.g. , Borrelia burgdorferi , Chlamydia trachomatis , Ureaplasma ) , history adverse reaction macrolides , roxithromycin , similar antibiotic . A patient could withdraw trial time enrollment follow reason : patient 's request , severe lifethreatening adverse event , inadequate control arthritis symptom ( &gt; 50 percent increase total number swell tender joint ) necessitate increase systemic corticosteroid dosage reinstitution therapy diseasemodifying antirheumatic drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Roxithromycin , Rheumatoid arthritis , Macrolides</keyword>
</DOC>